RNTECH and DNAVision announce a co-marketing agreement to offer complete solution for biomarker and target discovery
Privately held companies DNAVision and RNTECH announced that they have signed a co-marketing agreement under which the companies will jointly offer an integrated package of high quality material biological bank, gene expression and genotyping technologies. Post-genome era discovery processes must be based upon the combination of two key components: high quality, severely selected biological material associated with diagnostic and clinical data from large scale patient cohorts and state of the art technology platforms including genomics, proteomics and bioinformatics platforms.
The RNTECH/DNAVision offer associates these key components, creating a opportunity for pharmaceutical and biotechnology industries to access discovery and development expertise in oncology for biomarker and drugable target discovery and development.
Most read news
Topics
Organizations
Other news from the department business & finance
Get the analytics and lab tech industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents
Closing in on mystery surrounding dangerous blood syndromes - Genetically driven MDS enabled by gene linked to metabolism and oxygen in cells
Significant breakthrough in the chemistry of fluorinated compounds - Overcoming the “Fluoro Wall”: Researchers observe tunneling effect of heavy atoms for the first time
Johnson & Johnson Nordic AB Acquires Amic - Gains Access to In Vitro Diagnostic Technologies in Development for Use in Point-of-Care Settings
Agilent Technologies Announces Strategic Partnership with Pacific Laboratory Products in Australia
Domainex Ltd wins biotechnology innovation award
Sequenom Announces European Licensing Agreement With LifeCodexx
Waters to Acquire Andrew Alliance
Gold shines through properties of nano biosensors - Fluorescence in ligand-protected gold nanoclusters is an intrinsic property of the gold particles themselves
Out of REACH - New legislation threatens medicines
Neutrons for the quantum technologies of the future: breakthrough results on layered perovskites